Tech Company Financing Transactions

CatalYm Funding Round

CatalYm, operating out of Planegg, Martinsri, received $150 million from Bioqube Ventures, Canaan Partners and Brandon Capital Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Am Klopferspitz 19 Martinsried
Planegg, Martinsri, 82152
DE

Phone

+49 (0)89 2000 664 4

Website

www.catalym.com

Email Address

[email protected]

Overview

Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company's services engage in developing antibodies that transform the tumor micro-environment and substantially improve treatment options by making tumors accessible and susceptible again to the patient's own immune system, enabling cancer patients to improve their survival and quality of life.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Phil L'Huillier

        

Chief Financial Officer

Anne Burger

        

Chief Medical Officer

Eugen Leo

        

Browse more venture capital transactions:

Prev: 7/16/2024: Monetary Metals venture capital transaction
Next: 7/16/2024: Arcee.ai venture capital transaction

Share this article

Where The Data Comes From

We document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary